Who
Edmund Harrigan
Director
Company insider
Files Form 4 as: Director, Incyte; Director, ACADIA Pharmaceuticals; Director, PhaseBio Pharmaceuticals; Director, Karuna Therapeutics; Director, Bellicum Pharmaceuticals.
In numbers
- Trades disclosed
- 106
- Buys
- 2
- Sells
- 3
- Bought
- $58K
- Sold
- $4.5M
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 25 Nov 2015
- Last trade
- 30 Sep 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Sep 2026filed 2 Oct 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code A | $25K206 at $121.35 | filing |
| 30 Jun 2026filed 2 Jul 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code A | $29K255 at $113.36 | filing |
| 30 Jun 2026filed 2 Jul 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code A | $29K255 at $113.36 | filing |
| 8 Jun 2026filed 10 Jun 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code A | —1,642 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —6,111 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —6,111 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code A | —1,642 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —8,107 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —8,107 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —16,004 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —8,107 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —16,004 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —9,311 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —9,311 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —8,107 | filing |
| 31 Mar 2026filed 2 Apr 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code A | $25K269 at $94.12 | filing |
| 31 Mar 2026filed 2 Apr 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code A | $25K269 at $94.12 | filing |
| 31 Dec 2025filed 5 Jan 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code A | $24K245 at $98.77 | filing |
| 31 Dec 2025filed 5 Jan 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code A | $24K245 at $98.77 | filing |
| 30 Sep 2025filed 2 Oct 2025 | INCY IncyteLife-science tools | SEC FORM 4 Code A | $25K289 at $84.81 | filing |
News
Head-To-Head Comparison: ACADIA Pharmaceuticals (NASDAQ:ACAD) versus C4 Therapeutics (NASDAQ:CCCC)ACAD · tickerreport.com · 19 Oct 2026Critical Review: ACADIA Pharmaceuticals (NASDAQ:ACAD) and C4 Therapeutics (NASDAQ:CCCC)ACAD · dailypolitical.com · 15 Oct 2026ACADIA Pharmaceuticals (NASDAQ:ACAD) Cut to "Neutral" at UBS GroupACAD · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name Edmund Harrigan; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.